Expert Ratings for Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) received 4 analyst ratings in the last quarter, with an average price target of $81.0, representing an upside from the current price of $60.29. The ratings included 1 bullish and 3 somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The current average price target has decreased by 1.22% from the previous target of $82.00. Analysts typically review stocks quarterly, basing their ratings on financial statements, meetings, and insider information.
December 11, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received mostly positive ratings from analysts, with an average price target suggesting a significant upside potential from the current stock price.
The positive analyst ratings and the higher price target compared to the current stock price suggest optimism about Intra-Cellular Therapies' future performance. This could lead to increased investor confidence and a potential rise in the stock price in the short term. The slight decrease in the average price target may slightly temper expectations but does not significantly alter the overall positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100